ADRX

12.8609.18%
AR

A. Robert MacLeod

Chief Scientific Officer

Dr. A. Robert MacLeod, Ph.D., serves as a Chief Scientific Officer at ADARx Pharmaceuticals, Inc., since January 2023. Dr. MacLeod joins ADARx as ADX-324 for the treatment of hereditary angioedema is enrolling healthy volunteers for its phase I clinical trial. Prior to ADARx, Dr. MacLeod served as the Chief Scientific Officer at Flamingo Therapeutics after holding several positions at Ionis Pharmaceuticals, as Vice President and Franchise Head of Oncology. He has led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of novel investigational therapeutics and over high impact scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University in Montreal Canada and his Ph.D. in Cancer Epigenetics from McGill University.

Positions